A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Chlordiazepoxide Clonazepam

Chlordiazepoxide vs Clonazepam — $114.8M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Benzodiazepine
Chlordiazepoxide
First FDA approval:
Benzodiazepine
Clonazepam
Brand: Klonopin
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.142Per unit
$0.021Per unit
Average NADACAcross all dosage forms and strengths
$0.164Up to $0.188
$0.298Up to $3.88
Generic manufacturersActive ANDA holders — FDA Orange Book
39 total ANDAs filed
1139 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$1.5MFull year
$113.3MFull year
Part D claims (CY24)Total fills, all strengths
145K44K beneficiaries
13.2M2.4M beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$10Per claim, all NDCs
$9Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
30Minimal friction
56Minimal friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
10Limited friction
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
Active shortageSee drug profile
Generic availableFDA Orange Book
Yes3 manufacturers
Yes11 manufacturers